As Poslovni Dnevnik writes on the 16th of October, 2020, while thousands of scientists around the world are still working on developing a vaccine against the new coronavirus, as well as developing drugs to help deal with the more serious symptoms of COVID-19, some companies have already embarked on building the capacities needed to produce vaccines. One Samobor company is among them.
The American company Moderna, which is developing its own vaccine for COVID-19, mRNA-1273, has already started strengthening its production capacities. In partnership with the Swiss company Lonza, they agreed to produce the vaccine at two locations – in the United States and much closer to home here in Europe in Switzerland.
As it is expected that Moderna’s vaccine, which is currently in the third and final phase of testing, will get the green light for production by the end of the year, it has been agreed to start expanding production capacities, according to a report from Zimo.
The value of the project is estimated at 210 million Swiss francs (1.499 billion kuna), and the construction of the plant in the Swiss city of Vispo should be completed within eight months, instead of two years which is otherwise the practice.
”Everything will be ready for the production of the first doses in December,” assures construction site manager Torsten Schmidt. Three production lines will be installed at the plant, which will be able to produce a total of about 300 million doses of vaccine per year.
However, the real news, at least in Croatian terms, is that the Samobor company Klimaoprema was chosen as the main designer and contractor, which, in cooperation with the company for the development of the CRB production process from the USA, will be responsible for the entire project, until it is handed over to the owner at the end.
Although the details of the project itself are still inaccessible to the public, it is known that the plant being constructed by the aforementioned Samobor company will cover an area of approximately 2,500 m2 of CNC to C class.